BioMed Research International
Volume 2018 (2018), Article ID 6124628, 1 page
https://doi.org/10.1155/2018/6124628

Corrigendum

Corrigendum to “Selective Progesterone Receptor Modulators for the Medical Treatment of Uterine Fibroids with a Focus on Ulipristal Acetate”

Thomas Rabe,¹ Nicole Saenger,² Andreas D. Ebert,³ Thomas Roemer,⁴ Hans-Rudolf Tinneberg,⁵ Rudy Leon De Wilde,⁶ and Markus Wallwiener⁷

¹Deutsche Gesellschaft für Gynäkologische Endokrinologie und Fortpflanzungsmedizin, Germany
²Klinikum für Frauenheilkunde und Geburtshilfe, Frankfurt/M, Germany
³Praxis für Frauengesundheit, Gynäkologie und Geburtshilfe, Berlin, Germany
⁴Evangelisches Krankenhaus Weyertal gGmbH, Köln, Germany
⁵Universitätsklinik Gießen und Marburg, Campus Gießen, Germany
⁶Klinik für Frauenheilkunde, Geburtshilfe und Gynäkologische Onkologie; Universitätsklinik für Gynäkologie, Pius-Hospital Oldenburg, Germany
⁷Universitäts-Frauenklinik Heidelberg, Germany

Correspondence should be addressed to Thomas Rabe; thomas_rabe@yahoo.de

Received 16 October 2018; Accepted 18 October 2018; Published 28 November 2018

Copyright © 2018 Thomas Rabe et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

In the article titled “Selective Progesterone Receptor Modulators for the Medical Treatment of Uterine Fibroids with a Focus on Ulipristal Acetate” [1], the affiliation of the third author was incorrect. The corrected affiliation is shown above. In addition, the Conflicts of Interest section should be updated as follows:

The authors have each previously received financial support from Gedeon Richter, who market ulipristal acetate as ESMYA®. Thomas Rabe received fees for lectures, publications, and participation on the advisory board before retiring in 2016, Thomas Roemer received fees for lectures and consultancy work, Nicole Sänger has been a consultant for Gedeon Richter and has received travel expenses and lecture fees, Hans-Rudolf Tinneberg received fees for lectures, Andreas D. Ebert received financial support for lectures and the establishment of the Myom-Netwerk, Markus Wallwiener received a honorarium for a congress presentation, and Rudy Leon De Wilde was reimbursed for costs concerning a presentation on myoma surgery.

References

T. Rabe, N. Saenger, A. D. Ebert et al., “Selective progesterone receptor modulators for the medical treatment of uterine fibroids with a focus on ulipristal acetate,” BioMed Research International, vol. 2018, Article ID 1374821, 12 pages, 2018.